Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Alnylam Pharmaceuticals (ALNY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Alnylam Pharmaceuticals is one of 1026 individual stocks in the Medical sector. Colle ...

Alnylam Pharmaceuticals NASDAQ: ALNY stock price action has been volatile but is uptrending and has gained 100% in the last two years. The uptrend is driven by increasing expectations for market-disrupting heart treatment and could double the price again. The latest action has the market up more than 65% in the last two months and heading to the $350 to $415 range based on the technicals. Alnylam Pharmaceuticals TodayALNYAlnylam Pharmaceuticals$261.91 +5.70 (+2.22%) 52-Week Range$141.98▼$287.55Price Target$ ...

Shares of Alnylam Pharmaceuticals, Inc. (ALNY) were down 8.5% on Aug. 30, after the company announced detailed data from the phase III HELIOS-B, which evaluated its investigational RNAi therapeutic, Amvuttra (vutrisiran) for an expanded indication.The HELIOS-B study is seeking to expand the label of Amvuttra for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.Per the company, the HELIOS-B study met the primary endpoint, demonstrating a statistically significant reduction in th ...

Alnylam Pharmaceuticals (ALNY) , a commercial-stage company, focuses on developing novel therapeutics based on RNAi. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas — genetic medicines, cardio-metabolic disease and hepatic infectious disease. Alnylam currently markets four drugs — Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran).Portfolio of Marketed Drugs Boosts RevenuesAmvuttra, the company’s lead drug, is ...

Alnylam Pharmaceuticals (ALNY) reported second-quarter 2024 adjusted earnings of 56 cents per share against the Zacks Consensus Estimate of a loss of 74 cents. The improvement was primarily driven by the recognition of a payment of approximately $185 million, which was previously deferred, upon modifying Alnylam’s ongoing collaboration with Regeneron (REGN) . The company had incurred a loss of $1.62 per share in the year-ago quarter.The adjusted figure excluded items like stock-based compensation expenses a ...

Financial Data and Key Metrics Changes - In Q2 2024, Alnylam Pharmaceuticals achieved a 34% year-over-year growth in global net product revenues, totaling $410 million, primarily driven by a 37% increase in the TTR business [7][11][25] - The company raised its revenue guidance for the year by 11% at the midpoint, reflecting strong commercial performance [7][30] - Total product revenue for Q2 was $410 million, a 34% increase compared to Q2 2023, with TTR and rare franchises growing by 37% and 25%, respectively [25][26] Business Line Data and Key Metrics Changes - The TTR franchise generated $307 million in global net product revenues, marking a 16% increase from Q1 2024 and a 37% increase from Q2 2023 [11][12] - The rare disease franchise, including GIVLAARI and OXLUMO, reported $13 million in global revenues, with a 25% year-over-year growth [16] - GIVLAARI sales increased by 7% year-over-year, while OXLUMO saw a robust 68% growth [16] Market Data and Key Metrics Changes - In the U.S., combined sales of ONPATTRO and AMVUTTRA increased by 16% from Q1 and 40% year-over-year, driven by strong demand for AMVUTTRA [12] - Internationally, TTR franchise growth also increased by 16% from Q1 and 35% year-over-year, primarily due to AMVUTTRA demand [13] Company Strategy and Development Direction - Alnylam aims to become a top-tier biotech company by developing transformative medicines for rare and prevalent diseases, supported by a high-yielding pipeline [9] - The company is preparing for a potential launch of vutrisiran in ATTR cardiomyopathy, which is expected to significantly enhance its commercial portfolio [8][15] - Alnylam is focused on establishing vutrisiran as the standard of care in ATTR-CM, leveraging its strong relationships with TTR centers and integrated customer-facing teams [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving financial goals, including a compounded annual growth rate of over 40% and sustainable non-GAAP operating income [30] - The positive results from the HELIOS-B study are expected to position vutrisiran as a first-line treatment option, addressing significant unmet medical needs [19][38] Other Important Information - Alnylam plans to host a TTR Investor Day on October 9, 2024, to discuss its leadership in ATTR amyloidosis [9][31] - The company is advancing its pipeline with multiple clinical studies, including a supplemental NDA filing for vutrisiran in late 2024 [20][32] Q&A Session Summary Question: Can you discuss the reimbursement landscape in ATTR cardiomyopathy? - Management highlighted the importance of seamless patient access and minimizing co-pay burdens, leveraging the physician-administered nature of AMVUTTRA [33][35] Question: What feedback have you received from physicians regarding vutrisiran? - Physicians are enthusiastic about the potential of vutrisiran to become the standard of care, especially given the impressive HELIOS-B results [37][39] Question: Will you report KM curves and time to events kinetics at the ESC? - Management confirmed plans to provide detailed results, including baseline characteristics and primary endpoint data, at the upcoming ESC Congress [43][46] Question: Can you provide updates on the ALN-APP program? - The ALN-APP program is progressing well, with ongoing studies in both Alzheimer's disease and cerebral amyloid angiopathy [50][60] Question: How has the nature of discussions with physicians changed since Eplontersen's launch? - Discussions have evolved positively, with increased clarity on product differentiation and the potential for market growth [62][64] Question: What is the strategy for growing the market beyond taking share from tafamidis? - Management emphasized the importance of demonstrating the efficacy of vutrisiran and its unique mechanism of action to access a broader patient population [78][80]

For the quarter ended June 2024, Alnylam Pharmaceuticals (ALNY) reported revenue of $659.83 million, up 107% over the same period last year. EPS came in at $0.56, compared to -$2.21 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $448.44 million, representing a surprise of +47.14%. The company delivered an EPS surprise of +175.68%, with the consensus EPS estimate being -$0.74.While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...

Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of a loss of $0.74 per share. This compares to loss of $2.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 175.68%. A quarter ago, it was expected that this RNA interference drug developer would post a loss of $0.75 per share when it actually produced a loss of $0.16, delivering a surprise of 78.67%.Over t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq Stock Market LLC For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( ...

Wall Street analysts forecast that Alnylam Pharmaceuticals (ALNY) will report quarterly loss of $0.71 per share in its upcoming release, pointing to a year-over-year increase of 67.9%. It is anticipated that revenues will amount to $452.73 million, exhibiting an increase of 42% compared to the year-ago quarter.The current level reflects an upward revision of 2.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reapp ...